178 related articles for article (PubMed ID: 37023220)
1. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Kunwor R; Silver DP; Abu-Khalaf M
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):186-196. PubMed ID: 37023220
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Sun X; Xu S; Li Y; Lv X; Wei M; He M
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):245-256. PubMed ID: 36908219
[TBL] [Abstract][Full Text] [Related]
7. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Chen Z; Wang X; Li X; Zhou Y; Chen K
J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
[TBL] [Abstract][Full Text] [Related]
8. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
9. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Shao F; Duan Y; Zhao Y; Li Y; Liu J; Zhang C; He S
Aging (Albany NY); 2021 Mar; 13(6):8975-8988. PubMed ID: 33705352
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors Display Differential Efficacy in Models of
Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
[TBL] [Abstract][Full Text] [Related]
13. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
[TBL] [Abstract][Full Text] [Related]
14. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
17. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
18. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
20. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
